Vertex, CRISPR Therapeutics ink deal on sickle cell gene therapy Vertex Pharmaceuticals and CRISPR Therapeutics have amended their collaboration agreement to develop, manufacture, and commercialize CTX001, an ex vivo CRISPR/Cas9-based gene editing therapy being developed for the treatment of sickle cell disease and transfusion-dependent beta-thalassemia.Read More
Lineage, Immunomic to develop glioblastoma immunotherapy Lineage Cell Therapeutics and Immunomic Therapeutics have signed a worldwide license and development collaboration agreement to generate a novel candidate derived from Lineage's VAC allogeneic cancer immunotherapy platform, which targets a proprietary, tumor-associated antigen construct provided by Immunomic for the treatment of glioblastoma multiforme.Read More
Valo acquires PeptiBAC vaccine tech Valo Therapeutics has acquired the intellectual property rights to the University of Helsinki's PeptiBAC cancer and infectious disease vaccination technology.Read More